Literature DB >> 22231291

XMRV and prostate cancer--a 'final' perspective.

Karen S Sfanos1, Amanda L Aloia, Angelo M De Marzo, Alan Rein.   

Abstract

XMRV was first described in 2006, when it was identified in samples isolated from prostate cancer tissues. However, studies have since shown that XMRV arose in the laboratory and was formed by genetic recombination between two viral genomes carried in the germline DNA of mice used during serial transplantation of the CWR22 prostate cancer xenograft. These new findings strongly imply that XMRV does not circulate in humans, but is only present in the laboratory. Thus, there is no reason to believe that it has any role in the etiology of prostate cancer or other diseases.
© 2012 Macmillan Publishers Limited. All rights reserved

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22231291      PMCID： PMC4029112          DOI： 10.1038/nrurol.2011.225

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  65 in total

1.  Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study.

Authors:  Graham Simmons; Simone A Glynn; Anthony L Komaroff; Judy A Mikovits; Leslie H Tobler; John Hackett; Ning Tang; William M Switzer; Walid Heneine; Indira K Hewlett; Jiangqin Zhao; Shyh-Ching Lo; Harvey J Alter; Jeffrey M Linnen; Kui Gao; John M Coffin; Mary F Kearney; Francis W Ruscetti; Max A Pfost; James Bethel; Steven Kleinman; Jerry A Holmberg; Michael P Busch
Journal:  Science       Date:  2011-09-22       Impact factor: 47.728

2.  Human polyomaviruses and other human viruses in neuroendocrine tumors.

Authors:  Markus Schmitt; Daniela Höfler; Nadezda Koleganova; Michael Pawlita
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-05-25       Impact factor: 4.254

3.  XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH.

Authors:  Rebecca S Arnold; Natalia V Makarova; Adeboye O Osunkoya; Suganthi Suppiah; Takara A Scott; Nicole A Johnson; Sushma M Bhosle; Dennis Liotta; Eric Hunter; Fray F Marshall; Hinh Ly; Ross J Molinaro; Jerry L Blackwell; John A Petros
Journal:  Urology       Date:  2010-04       Impact factor: 2.649

4.  Recombinant origin of the retrovirus XMRV.

Authors:  Tobias Paprotka; Krista A Delviks-Frankenberry; Oya Cingöz; Anthony Martinez; Hsing-Jien Kung; Clifford G Tepper; Wei-Shau Hu; Matthew J Fivash; John M Coffin; Vinay K Pathak
Journal:  Science       Date:  2011-05-31       Impact factor: 47.728

5.  Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome.

Authors:  Harriet C T Groom; Virginie C Boucherit; Kerry Makinson; Edward Randal; Sarah Baptista; Suzanne Hagan; John W Gow; Frank M Mattes; Judith Breuer; Jonathan R Kerr; Jonathan P Stoye; Kate N Bishop
Journal:  Retrovirology       Date:  2010-02-15       Impact factor: 4.602

6.  Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections.

Authors:  Eleanor Barnes; Peter Flanagan; Anthony Brown; Nicola Robinson; Helen Brown; Myra McClure; Annette Oxenius; Jane Collier; Jonathan Weber; Huldrych F Günthard; Bernard Hirschel; Sarah Fidler; Rodney Phillips; John Frater
Journal:  J Infect Dis       Date:  2010-10-11       Impact factor: 5.226

7.  Analysis of XMRV integration sites from human prostate cancer tissues suggests PCR contamination rather than genuine human infection.

Authors:  Jeremy A Garson; Paul Kellam; Greg J Towers
Journal:  Retrovirology       Date:  2011-02-25       Impact factor: 4.602

8.  No association of xenotropic murine leukemia virus-related viruses with prostate cancer.

Authors:  William M Switzer; Hongwei Jia; Haoqiang Zheng; Shaohua Tang; Walid Heneine
Journal:  PLoS One       Date:  2011-05-04       Impact factor: 3.240

9.  No evidence of XMRV or related retroviruses in a London HIV-1-positive patient cohort.

Authors:  Eleanor R Gray; Jeremy A Garson; Judith Breuer; Simon Edwards; Paul Kellam; Deenan Pillay; Greg J Towers
Journal:  PLoS One       Date:  2011-03-23       Impact factor: 3.240

10.  Murine leukemia viruses: objects and organisms.

Authors:  Alan Rein
Journal:  Adv Virol       Date:  2011-11-15
View more
  12 in total

1.  Phylogenetic and biological analysis of a laboratory-generated gammaretrovirus xenotropic murine leukemia virus-related virus (XMRV).

Authors:  Xiaochu Ma; Shiying Zhou; Meili Wei; Yanxia Chen; Jiaqiang Li; Weiliang Xiong; Shibo Jiang; Chungen Pan
Journal:  Virus Genes       Date:  2012-06-27       Impact factor: 2.332

2.  Retraction for Schlaberg et al., XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors.

Authors:  Robert Schlaberg; Daniel J Choe; Kristy R Brown; Harshwardhan M Thaker; Ila R Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

3.  Infections and inflammation in prostate cancer.

Authors:  Karen S Sfanos; William B Isaacs; Angelo M De Marzo
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

4.  No evidence of xenotropic murine leukemia virus-related virus transmission by blood transfusion from infected rhesus macaques.

Authors:  Dhanya K Williams; Teresa A Galvin; Yamei Gao; Christina O'Neill; Dustin Glasner; Arifa S Khan
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

5.  In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer.

Authors:  Deanna Lee; Jaydip Das Gupta; Christina Gaughan; Imke Steffen; Ning Tang; Ka-Cheung Luk; Xiaoxing Qiu; Anatoly Urisman; Nicole Fischer; Ross Molinaro; Miranda Broz; Gerald Schochetman; Eric A Klein; Don Ganem; Joseph L Derisi; Graham Simmons; John Hackett; Robert H Silverman; Charles Y Chiu
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

6.  Identification of Pathogen Signatures in Prostate Cancer Using RNA-seq.

Authors:  Yunqin Chen; Jia Wei
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

Review 7.  If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease.

Authors:  Karen S Sfanos; Srinivasan Yegnasubramanian; William G Nelson; Tamara L Lotan; Ibrahim Kulac; Jessica L Hicks; Qizhi Zheng; Charles J Bieberich; Michael C Haffner; Angelo M De Marzo
Journal:  Asian J Urol       Date:  2018-12-12

8.  XMRV induces cell migration, cytokine expression and tumor angiogenesis: are 22Rv1 cells a suitable prostate cancer model?

Authors:  Kristin Stieler; Udo Schumacher; Andrea Kristina Horst; Nicole Fischer
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

9.  Infection of Xenotransplanted Human Cell Lines by Murine Retroviruses: A Lesson Brought Back to Light by XMRV.

Authors:  Heidi A Hempel; Kathleen H Burns; Angelo M De Marzo; Karen S Sfanos
Journal:  Front Oncol       Date:  2013-06-17       Impact factor: 6.244

10.  What can academia learn from XMRV studies?

Authors:  Chungen Pan; Xiaochu Ma; Shibo Jiang
Journal:  Nat Rev Urol       Date:  2012-02-14       Impact factor: 14.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.